161 related articles for article (PubMed ID: 18452618)
1. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier.
Yang R; Li WW; Hoang BH; Kim H; Banerjee D; Kheradpour A; Healey JH; Meyers PA; Bertino JR; Gorlick R
BMC Cancer; 2008 May; 8():124. PubMed ID: 18452618
[TBL] [Abstract][Full Text] [Related]
2. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells.
Worm J; Kirkin AF; Dzhandzhugazyan KN; Guldberg P
J Biol Chem; 2001 Oct; 276(43):39990-40000. PubMed ID: 11509559
[TBL] [Abstract][Full Text] [Related]
3. Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines.
Moscow JA; Connolly T; Myers TG; Cheng CC; Paull K; Cowan KH
Int J Cancer; 1997 Jul; 72(1):184-90. PubMed ID: 9212241
[TBL] [Abstract][Full Text] [Related]
4. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
Sowers R; Toguchida J; Qin J; Meyers PA; Healey JH; Huvos A; Banerjee D; Bertino JR; Gorlick R
Mol Cancer Ther; 2003 Jun; 2(6):535-41. PubMed ID: 12813132
[TBL] [Abstract][Full Text] [Related]
5. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
Serra M; Reverter-Branchat G; Maurici D; Benini S; Shen JN; Chano T; Hattinger CM; Manara MC; Pasello M; Scotlandi K; Picci P
Ann Oncol; 2004 Jan; 15(1):151-60. PubMed ID: 14679136
[TBL] [Abstract][Full Text] [Related]
6. Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells.
Ding BC; Witt TL; Hukku B; Heng H; Zhang L; Matherly LH
Biochem Pharmacol; 2001 Mar; 61(6):665-75. PubMed ID: 11266651
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
8. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.
Yang R; Kolb EA; Qin J; Chou A; Sowers R; Hoang B; Healey JH; Huvos AG; Meyers PA; Gorlick R
Clin Cancer Res; 2007 May; 13(9):2557-67. PubMed ID: 17473184
[TBL] [Abstract][Full Text] [Related]
9. Relationship between RFC gene expression and intracellular drug concentration in methotrexate-resistant osteosarcoma cells.
Wang JJ; Li GJ
Genet Mol Res; 2014 Jul; 13(3):5313-21. PubMed ID: 25078587
[TBL] [Abstract][Full Text] [Related]
10. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.
Kastrup IB; Worm J; Ralfkiaer E; Hokland P; Guldberg P; Grønbaek K
Eur J Haematol; 2008 Jan; 80(1):61-6. PubMed ID: 18028428
[TBL] [Abstract][Full Text] [Related]
12. A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
Zhao R; Gao F; Hanscom M; Goldman ID
Clin Cancer Res; 2004 Jan; 10(2):718-27. PubMed ID: 14760095
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of methotrexate resistance in osteosarcoma.
Guo W; Healey JH; Meyers PA; Ladanyi M; Huvos AG; Bertino JR; Gorlick R
Clin Cancer Res; 1999 Mar; 5(3):621-7. PubMed ID: 10100715
[TBL] [Abstract][Full Text] [Related]
14. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.
Hattinger CM; Reverter-Branchat G; Remondini D; Castellani GC; Benini S; Pasello M; Manara MC; Scotlandi K; Picci P; Serra M
Eur J Cell Biol; 2003 Sep; 82(9):483-93. PubMed ID: 14582536
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss.
Kaufman Y; Ifergan I; Rothem L; Jansen G; Assaraf YG
Blood; 2006 Apr; 107(8):3288-94. PubMed ID: 16368880
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma.
Yang R; Qin J; Hoang BH; Healey JH; Gorlick R
Clin Orthop Relat Res; 2008 Sep; 466(9):2046-51. PubMed ID: 18528741
[TBL] [Abstract][Full Text] [Related]
17. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression.
Gorlick R; Goker E; Trippett T; Steinherz P; Elisseyeff Y; Mazumdar M; Flintoff WF; Bertino JR
Blood; 1997 Feb; 89(3):1013-8. PubMed ID: 9028333
[TBL] [Abstract][Full Text] [Related]
18. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
19. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells.
Corona G; Giannini F; Fabris M; Toffoli G; Boiocchi M
Int J Cancer; 1998 Jan; 75(1):125-33. PubMed ID: 9426700
[TBL] [Abstract][Full Text] [Related]
20. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
